ID
26274
Description
Study ID: 101468/196 Clinical Study ID: 101468/196 Study Title: 101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00650104 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Parkinson DiseaseA Long-Term, Open-Label Continuation Study of Once Daily Adminstration of Ropinirole CR Tablets to Patients with Parkinson's Disease Who Completed the Previous Ropinirole CR Studies - 167 & 164 Ongoing Record: Adverse Events
Keywords
Versions (1)
- 10/15/17 10/15/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 15, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC-ND 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Adverse Events Ropinirole in Parkinson's Disease GSK 101468/196
Adverse Events Ropinirole in Parkinson's Disease GSK 101468/196
- StudyEvent: ODM
Description
Adverse Events
Alias
- UMLS CUI-1
- C0877248
Description
If YES, indicate below.
Data type
boolean
Alias
- UMLS CUI [1]
- C0877248
Description
Adverse Event Diagnosis
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0011900
Description
* A Serious Adverse Event is any AE that is fatal, life-threatening , disabling/incapacitating, results in inpatient hospitalization or prolongation of existing hospitalization, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgement, they may jeopardise the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Cancer, overdose and pregnancy must also be reported on SAE form. Record any Serious Adverse Events on the Serious Adverse Event from and notify the PAREXEL Clinical Trial Safety Center within 24 hours of learning of its occurence
Data type
boolean
Alias
- UMLS CUI [1]
- C1710056
Description
Start Date
Data type
date
Measurement units
- dd-mmm-yyyy
Alias
- UMLS CUI [1]
- C0808070
Description
Start Time
Data type
time
Measurement units
- 24hr:min
Alias
- UMLS CUI [1]
- C1301880
Description
If ongoing, please eave blank.
Data type
date
Measurement units
- dd-mmm-yyyy
Alias
- UMLS CUI [1]
- C0806020
Description
End Time
Data type
time
Measurement units
- 24hr:min
Alias
- UMLS CUI [1]
- C1522314
Description
Adverse Event: Intensity
Data type
integer
Alias
- UMLS CUI [1]
- C1710066
Description
Relationship to Drug
Data type
integer
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0013230
- UMLS CUI [1,3]
- C0439849
Description
Action Taken
Data type
integer
Alias
- UMLS CUI [1]
- C2826626
Description
If YES, record on Other (non-study) Medications Form.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
Description
Event Course
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0750729
Description
Number of Adverse Events
Data type
float
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0449788
Description
Adverse Event Outcome
Data type
integer
Similar models
Adverse Events Ropinirole in Parkinson's Disease GSK 101468/196
- StudyEvent: ODM
C0011900 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0750729 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,2])